scientists were mismanaging money, and the concern of LSD causing chromosome damage in 1969 led to further negative attitudes toward the study. Termination The studies at Spring Grove State Hospital ended in 1976. Several factors led to the termination of the Spring Grove Experiment. In 1971 Walter Pahnke, the director of clinical science and leader of the Spring Grove research team at the time, died. His successor had no background in psychedelic research and therefore did not have the experience or drive to continue the experimentation being led by Pahnke before he died. The Maryland Psychiatric Research Center was accused of improper use of public money and not engaging in real treatment that would be beneficial to the public. When legislation was passed resulting in the detraction of funding from state hospitals, animosity grew between the more privileged researchers and the hospital employees. This discouraged workers from getting involved in experiments, adding to the growing negative atmosphere around LSD research. In addition, controversy surrounding the use of LSD in experiments surfaced. Among these controversies include reports of a suicide in Project MKUltra and treatment with LSD without informed consent at Edgewood Arsenal in the late 1970s. Because the arsenal had ties to the University of Maryland, there was dramatic pressure to discontinue all research involving psychedelics as treatment. The accumulation of these reports, along with general reservations about medicalizing what the media portrayed as strictly deleterious, led to the termination of the psychedelic experiments on human subjects at Spring Grove. Legacy By 1976, more than 700 patients were treated with psychedelic drugs. This produced positive yet equivocal results. Most benefitted, and a minority did not display any response, however, there is no awareness of long-term complications. By the 1970s, LSD was no longer recognized as having a medical use. It was instead seen as having a great potential for abuse and addiction. In the 1990s, even when Dr. Yensen and Dr. Kurland received FDA approval to continue LSD research, they were unable to acquire the LSD for clinical study in the United States. Today, LSD research is gradually re-emerging as a focus for clinical researchers. In 2014, there was a study on the effects of LSD and psychotherapy on patients experiencing anxiety. In 2013, studies were being done on patients experiencing Post Traumatic Stress Disorder combining MDMA and psychotherapy; and in 2016, an article was released announcing the FDA's approval